Market Place
Sourcing Support
Baxter`s Generics Eribulin mesylste Receives Approval in US
01 Oct 2024 //
FDA
Jiangxi Qingfeng`s Generic Eribulin Mesylate Receives Approval in US
28 Jun 2024 //
FDA
EVER Pharma gained EU-Approval for Advanced Cancer Treatment
16 Apr 2024 //
PRESS RELEASE
Gland Pharma receives USFDA approval for Eribulin Mesylate Injection
07 Apr 2024 //
INDINPHARMAPOST
EVER Pharma Announces Approval of Testosterone Undecanoate in the EU
13 Mar 2024 //
PRESS RELEASE
Eisai to Present Preclinical & Clinical Research on Eribulin at Cancer Symposium
01 Dec 2022 //
PRNEWSWIRE
Eisai Presents Results of Post-Hoc Analysis of Eribulin Mesylate
11 Sep 2022 //
PRNEWSWIRE
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2021
14 Sep 2021 //
ACNNEWSWIRE
Eisai Announces Real-World Data on the Effectiveness of HALAVEN®
18 May 2021 //
PRNEWSWIRE
Eisai Presents Ph I Clinical Trial On Liposomal Halaven® (Eribulin) At ESMO
18 Sep 2020 //
PRESS RELEASE
Eisai to Present Latest Data from Oncology Pipeline at ASCO 2020, KEYTRUDA®
13 May 2020 //
PRNEWSWIRE
Eisai launches anti cancer agent Halaven in China
16 Jan 2020 //
BIOSPECTRUM ASIA
launch of anticancer agent halaven® in china
10 Jan 2020 //
GLOBE NEWSWIRE
Eisai`s Promotion & Agreement & Mylan India for Eribulin IInd Brand in India
25 Sep 2019 //
BIOSPACE
Eisai, Mylan to promote anti-cancer drug brands in India
23 Sep 2019 //
BIOAPECTRUMASIA
Eisai’s Halaven cleared for breast cancer in China
17 Jul 2019 //
THE PHARMALETTER
Eisai`s Phase 1 Trial of HALAVEN® with Polyphor`s CXCR4 Antagonist Balixafortide
04 Jun 2019 //
PR NEWSWIRE
NICE turns down earlier use of Eisai’s Halaven
29 Nov 2017 //
PHARMA TIMES
AstraZeneca Phase III breast cancer trial met primary endpoint
23 Feb 2017 //
EUROPEAN PHARMACEUTICAL
Eisai`s Lenvima moves toward Nexavar showdown with phase 3 liver cancer win
26 Jan 2017 //
FIERCE PHARMA
Halozyme`s Pancreatic Cancer Drug Succeeds in Mid-stage Trial
06 Jan 2017 //
REUTERS
Japanese Companies Make Cautious Return to Indian Pharma Market
04 Jan 2017 //
ECONOMIC TIMES
Merck, Eisai Announce Interim Data Investigating Keytruda, Halaven Combination
12 Dec 2016 //
NASDAQ
Eisai wins NICE backing for older Halaven but still isn`t happy about Lenvima
03 Nov 2016 //
FIERCE PHARMA
Life-extending breast cancer drug approved by NICE
03 Nov 2016 //
EU PHARMACEUTICAL REVIEW
Eisai Latest Cancer Drugmaker to Win UK Approval After Price Cut
03 Nov 2016 //
REUTERS
Eisai`s LENVIMA Nominated for Galien Foundation`s Best Pharmaceutical Product
26 Oct 2016 //
PR NEWSWIRE
New Halaven (eribulin) & Lenvima Data to be Presented at ESMO Demonstrate
29 Sep 2016 //
PRNEWSWIRE
Patient in Germany, Austria with advanced liposarcoma now have access to Halaven
09 May 2016 //
PR NEWSWIRE
EU nod for Eisai`s Halaven in liposarcoma
05 May 2016 //
PHARMATIMES
FDA approves Eisai`s drug Halaven for type of soft tissue cancer
28 Jan 2016 //
FDA
Halozyme,Eisai to present data of PEGPH20 in combination with eribulin mesylate
09 Dec 2015 //
PR NEWS WIRE
Swiss drugmaker Roche launches costliest cancer drugs in India
25 Nov 2015 //
ECONOMIC TIMES
Takeda crosses Actos settlement threshold as 96% of plaintiffs seek resolution
14 Sep 2015 //
FIERCE PHARMA ASIA
Eisai drug derived from sea sponges shows sarcoma treatment promise
31 May 2015 //
FIERCE PHARMA ASIA
Bayer`s Stivarga wins appeal to stay on CDF
23 May 2015 //
PHARMA TIMES
England`s Cancer Drugs Fund Changes Its Tune, Holds onto Novartis` Afinitor
19 Mar 2015 //
FIERCE PHARMA
Cancer Drugs Fund a ‘missed opportunity’, says MP
14 Mar 2015 //
PMLIVE
Eisai and Merck in Cancer Combo Deal
05 Mar 2015 //
PHARMATIMES
25 Cancer Drugs to Be Denied on NHS
12 Jan 2015 //
THE TELEGRAPH
